LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Home・Akcijų sąrašas・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

39.46 -1.52

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

39.17

Max

40.37

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -130M
Pardavimai	-888K 143K
Pelno marža	-90,972.727
Darbuotojai	437
EBITDA	-12M -142M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+119.34% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	454M 4.5B
Ankstesnė atidarymo kaina	40.98
Ankstesnė uždarymo kaina	39.46

Naujienos nuotaikos

By Acuity

71%

29%

317 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

30.39 / 33.46 Palaikymas ir pasipriešinimas

Crinetics Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-03 18:43; UTC

Svarbiausios naujienos

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026-03-03 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026-03-03 23:45; UTC

Rinkos pokalbiai

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026-03-03 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-03 22:38; UTC

Svarbiausios naujienos

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026-03-03 22:16; UTC

Uždarbis

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026-03-03 22:09; UTC

Uždarbis

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026-03-03 22:06; UTC

Uždarbis

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026-03-03 22:05; UTC

Uždarbis

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026-03-03 22:03; UTC

Uždarbis

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Tech, Media & Telecom Roundup: Market Talk

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-03 21:45; UTC

Svarbiausios naujienos

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026-03-03 21:37; UTC

Uždarbis

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026-03-03 21:26; UTC

Svarbiausios naujienos

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026-03-03 20:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026-03-03 20:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026-03-03 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold and Silver Drop as Energy Surges -- Market Talk

2026-03-03 18:43; UTC

Uždarbis

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026-03-03 18:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026-03-03 18:14; UTC

Uždarbis

How Long Can Anthropic Play Defense? -- WSJ

2026-03-03 17:41; UTC

Svarbiausios naujienos

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026-03-03 17:36; UTC

Svarbiausios naujienos

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026-03-03 17:28; UTC

Įsigijimai, susijungimai, perėmimai

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Akcijų palyginimas

Kainos pokytis

Crinetics Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

119.34% į viršų

12 mėnesių prognozė

Vidutinis 88 USD 119.34%

Aukščiausias 97 USD

Žemiausias 67 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Crinetics Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Crinetics Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

30.39 / 33.46Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

317 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.